Company

ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program- platforms that blend seamlessly with IPA’s Artemis Intelligence Metadata (AIM)™ capabilities to enable rapid turnaround on additional algorithmic outputs in therapeutic optimization, stability, affinity and manufacturability.

IPA is focused on the next generation of antibody discovery, to deliver therapeutically relevant antibodies, in a short period of time, with high probability of succeeding to clinical trials. With over 30 years of experience in the custom antibody business, we have completed roughly 4000 projects for hundreds of clients across the globe, including a majority of the top 20 largest pharmaceutical companies.
Our discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and Victoria, British Columbia (IPA Canada) with headquarters located in Fargo, North Dakota. We operate multi-nationally to offer a continuum of antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.
We are comprised of experienced research and development scientists that encompass a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs.

Management Team

Dr. Jennifer Bath

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang

Chief Business Officer

View Bio

Dr. Stefan Lang joined ImmunoPrecise Antibodies as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

Dr. Yasmina Abdiche

Chief Scientific Officer

View Bio

Dr. Yasmina Abdiche joined ImmunoPrecise Antibodies in April 2020 as Chief Scientific Officer and will lead the company’s global research and development team. She was previously CSO at Carterra, where she helped to transition the LSA antibody screening technology to global commercialization. Prior to that, she had a twelve-year career at Rinat, Pfizer's biotherapeutic site, where she led a core team of analytical scientists performing antibody characterization on label-free biosensors. As a Research Fellow, she also served on Rinat’s Leadership Team and on the Governing Committee for Pfizer's Post-doctoral Program. She holds over twelve issued patents in the antibody space and is co-inventor of a PD-1 inhibitor (Sasanlimab, PF06801591, RN888) and of a market-approved anti-CGRP antibody for migraine, Ajovy

Dr. Abdiche graduated from Oxford University in the UK with a Master's degree in Chemistry and a Ph.D. in Biological Chemistry. She has co-authored over 40 peer-reviewed publications in the application of label-free biosensors to drug discovery and has given numerous invited presentations at conferences worldwide.

Kari Graber

VP of Client Relations and Project Management

View Bio

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Dr. Debby Kruijsen

General Manager, ImmunoPrecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, ImmunoPrecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Dr. Jennifer Bath

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang

Chief Business Officer

View Bio

Dr. Stefan Lang joined ImmunoPrecise Antibodies as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

Dr. Yasmina Abdiche

Chief Scientific Officer

View Bio

Dr. Yasmina Abdiche joined ImmunoPrecise Antibodies in April 2020 as Chief Scientific Officer and will lead the company’s global research and development team. She was previously CSO at Carterra, where she helped to transition the LSA antibody screening technology to global commercialization. Prior to that, she had a twelve-year career at Rinat, Pfizer's biotherapeutic site, where she led a core team of analytical scientists performing antibody characterization on label-free biosensors. As a Research Fellow, she also served on Rinat’s Leadership Team and on the Governing Committee for Pfizer's Post-doctoral Program. She holds over twelve issued patents in the antibody space and is co-inventor of a PD-1 inhibitor (Sasanlimab, PF06801591, RN888) and of a market-approved anti-CGRP antibody for migraine, Ajovy

Dr. Abdiche graduated from Oxford University in the UK with a Master's degree in Chemistry and a Ph.D. in Biological Chemistry. She has co-authored over 40 peer-reviewed publications in the application of label-free biosensors to drug discovery and has given numerous invited presentations at conferences worldwide.

Kari Graber

VP of Client Relations and Project Management

View Bio

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Dr. Debby Kruijsen

General Manager, ImmunoPrecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, ImmunoPrecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Board of Directors

James Kuo, MD, MBA

Chairman

Committee Served: Audit

View Bio

Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Dr. Jennifer Bath

Director

Committees Served: Finance (ad hoc)

View Bio

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Audit & Compensation

View Bio

Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).

Paul Andreola

Director

Committees Served: Compensation & Nomination & Finance (ad hoc)

View Bio

Paul Andreola has over 20 years of business development and financial markets experience including senior management, marketing, and communications roles for early stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and has facilitated multiple early stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of NameSilo Technologies (URL:CSE) and Ironwood Capital Corp. (TSXV: IRN.P).

Dr. Robert D. Burke

Director

Committees Served: Audit & Nomination

View Bio

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.

Brian Lundstrom

Director

View Bio

Brian Lundstrom has over 30 years’ experience in biotech. He started his career in product and clinical development for Novo Nordisk in Europe, in 1987, prior to moving to the US for business development work. He subsequently served at OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. Mr. Lundstrom was involved in SangStat’s $600M sale and integration into Genzyme in 2003.

Since 2011, Mr. Lundstrom has established global business leadership in transgenic animals for the discovery of human, therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. Mr. Lundstrom is also the founder and CEO of Abvivo, LLC.

James Kuo, MD, MBA

Chairman

Committee Served: Audit

Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Brian Lundstrom

Director

Brian Lundstrom has over 30 years’ experience in biotech. He started his career in product and clinical development for Novo Nordisk in Europe, in 1987, prior to moving to the US for business development work. He subsequently served at OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. Mr. Lundstrom was involved in SangStat’s $600M sale and integration into Genzyme in 2003.

Since 2011, Mr. Lundstrom has established global business leadership in transgenic animals for the discovery of human, therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. Mr. Lundstrom is also the founder and CEO of Abvivo, LLC.

Dr. Jennifer Bath

Director

Committees Served: Finance (ad hoc)

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Audit & Compensation

Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & as well as Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd., which collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).

Paul Andreola

Director

Committees Served: Compensation & Nomination & Finance (ad hoc)

Paul Andreola has over twenty years' of business development and financial markets experience including senior management, marketing, and communications roles for early-stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and facilitated multiple early-stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of NameSilo Technologies (URL:CSE) and Ironwood Capital Corp. (TSXV: IRN.P).

Dr. Robert D. Burke

Director

Committees Served: Audit & Nomination

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc and a PhD at the University of Alberta.

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™

VICTORIA, November 25, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

November 25, 2020

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

VICTORIA, November 23, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 23, 2020

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

VICTORIA, November 19, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 19, 2020

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

VICTORIA, BC, November 17, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 17, 2020

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

VICTORIA, BC, November 9, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 9, 2020

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

VICTORIA, BC, November 4, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

November 4, 2020

Your Privacy Matters

As part of ImmunoPrecise's shared values of Innovation, Collaboration, and Ownership, we take seriously the responsibility to protect our customer's intellectual property. Data drives every decision in the laboratory, ensuring its accurate and protected at every step is crucial in the success of our customer's projects. ImmunoPrecise has taken a defense-in-depth approach through industry-leading AI-enabled security technologies to protect intellectual property, and data from policy violations, intrusion, and breaches. Security and privacy concerns can be directed to: privacy@immunoprecise.com